Pharmacology and therapeutics of bronchodilators M Cazzola, CP Page, L Calzetta, MG Matera Pharmacological Reviews 64 (3), 450-504, 2012 | 534 | 2012 |
ACE2: the major cell entry receptor for SARS-CoV-2 F Scialo, A Daniele, F Amato, L Pastore, MG Matera, M Cazzola, ... Lung 198, 867-877, 2020 | 434 | 2020 |
β2-Agonist Therapy in Lung Disease M Cazzola, CP Page, P Rogliani, MG Matera American journal of respiratory and critical care medicine 187 (7), 690-696, 2013 | 322 | 2013 |
A systematic review with meta-analysis of dual bronchodilation with LAMA/LABA for the treatment of stable COPD L Calzetta, P Rogliani, MG Matera, M Cazzola Chest 149 (5), 1181-1196, 2016 | 271 | 2016 |
Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia M Cazzola, F Imperatore, A Salzillo, F Di Perna, F Calderaro, ... Chest 114 (2), 411-415, 1998 | 269 | 1998 |
Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis M Cazzola, L Calzetta, C Page, J Jardim, AG Chuchalin, P Rogliani, ... European Respiratory Review 24 (137), 451-461, 2015 | 259 | 2015 |
Optimizing drug delivery in COPD: the role of inhaler devices P Rogliani, L Calzetta, A Coppola, F Cavalli, J Ora, E Puxeddu, ... Respiratory medicine 124, 6-14, 2017 | 217 | 2017 |
The effect of N-acetylcysteine on biofilms: Implications for the treatment of respiratory tract infections F Blasi, C Page, GM Rossolini, L Pallecchi, MG Matera, P Rogliani, ... Respiratory medicine 117, 190-197, 2016 | 210 | 2016 |
Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response study M Cazzola, MG Matera, G Santangelo, A Vinciguerra, F Rossi, G D'amato Respiratory medicine 89 (5), 357-362, 1995 | 209 | 1995 |
β2‐adrenoceptor agonists: current and future direction M Cazzola, L Calzetta, MG Matera British journal of pharmacology 163 (1), 4-17, 2011 | 206 | 2011 |
Severe respiratory SARS-CoV2 infection: Does ACE2 receptor matter? F Perrotta, MG Matera, M Cazzola, A Bianco Respiratory medicine 168, 105996, 2020 | 193 | 2020 |
TNF-α inhibitors in asthma and COPD: we must not throw the baby out with the bath water MG Matera, L Calzetta, M Cazzola Pulmonary pharmacology & therapeutics 23 (2), 121-128, 2010 | 191 | 2010 |
Inhaled β2-Adrenoceptor Agonists: Cardiovascular Safety in Patients with Obstructive Lung Disease M Cazzola, MG Matera, CF Donner Drugs 65, 1595-1610, 2005 | 186 | 2005 |
Novel long‐acting bronchodilators for COPD and asthma M Cazzola, MG Matera British journal of pharmacology 155 (3), 291-299, 2008 | 178 | 2008 |
The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD M Cazzola, F Di Marco, P Santus, B Boveri, M Verga, MG Matera, ... Pulmonary pharmacology & therapeutics 17 (1), 35-39, 2004 | 178 | 2004 |
Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: a systematic review and meta-analysis P Rogliani, L Calzetta, F Cavalli, MG Matera, M Cazzola Pulmonary pharmacology & therapeutics 40, 95-103, 2016 | 169 | 2016 |
Ultra long-acting β2-agonists in development for asthma and chronic obstructive pulmonary disease M Cazzola, MG Matera, J Lötvall Expert opinion on investigational drugs 14 (7), 775-783, 2005 | 143 | 2005 |
The functional impact of adding salmeterol and tiotropium in patients with stable COPD M Cazzola, S Centanni, P Santus, M Verga, M Mondoni, F Di Marco, ... Respiratory medicine 98 (12), 1214-1221, 2004 | 136 | 2004 |
5-HT modifiers as a potential treatment of asthma M Cazzola, MG Matera Trends in pharmacological sciences 21 (1), 13-16, 2000 | 131 | 2000 |
Relationship between zinc and obesity. G Di Martino, MG Matera, B De Martino, C Vacca, S Di Martino, F Rossi Journal of medicine 24 (2-3), 177-183, 1993 | 127 | 1993 |